Clinical Trials Browser

Not yet recruiting × Interventional × Interleukin-2 × Clear all

Ovarian Neoplasms

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07183852 2025-09-19

GoTIL-01

Phase 1 Not yet recruiting

18 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT07105176 2025-08-19

HS-IT101 Injection for Advanced NSCLC

Phase 1 Not yet recruiting

12 enrolled

Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

10 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05810792 2023-11-22

PANCEP-1

Phase 2 Not yet recruiting

50 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT06107894 2023-10-30

TIL Therapy for Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

12 enrolled

Thoracic

Lung Neoplasms

NCT05903937 2023-06-15

HAITILS-PHP

Phase 1 Not yet recruiting

6 enrolled

Dermatologic

Uveal Melanoma, Melanoma

Clinical Trials

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

GoTIL-01

HS-IT101 Injection for Advanced NSCLC

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

PANCEP-1

TIL Therapy for Patients With Advanced Solid Tumors

HAITILS-PHP